Danirixin Dose Ranging Study in Adults With COPD
Pulmonary Disease, Chronic Obstructive
Enrolment: 614 · Results not recorded
Loading the evidence…
Biologic · ChEMBL not queried: the source names an antibody class with no named product. CLASS-LEVEL translation only. NO human trial uses a CXCR2 NEUTRALISING ANTIBODY; all 4 recorded trials use SMALL-MOLECULE CXCR2 antagonists (AZD5069, danirixin/GSK1325756) in prostate cancer and COPD, none in a trauma or injury indication, and 2 of the 4 are TERMINATED. NCT04552743 (MGTA-145) was DELIBERATELY REJECTED because it is a CXCR2 AGONIST used for stem-cell mobilisation, the pharmacological opposite. The interleukin-6 disruption arm was not separately queried within budget, an acknowledged omission.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Pulmonary Disease, Chronic Obstructive
Enrolment: 614 · Results not recorded
Pulmonary Disease, Chronic Obstructive
Enrolment: 19 · Results not recorded
Metastatic Castration Resistant Prostate Cancer
Enrolment: 30 · Results not recorded
Pulmonary Disease, Chronic Obstructive
Enrolment: 20 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Acute aortic dissection produced by angiotensin II infusion in mice preconditioned with a lysyl oxidase inhibitor (beta-aminopropionitrile)
Dissection developed within 24 h and about 70 per cent of mice died of aortic rupture. Anti-CXCR2 reduced neutrophil accumulation, lowered local and systemic interleukin-6 and limited aortic rupture, while interleukin-6 disruption suppressed dilatation and rupture without altering dissection incide…
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.